A Phase II Simon Two-Stage Efficacy Study of Intracerebral CTX-DP in Patients with Stable Paresis of the Arm Following an Ischaemic Stroke

脑内 CTX-DP 对缺血性中风后手臂稳定麻痹患者的 II 期西蒙两阶段疗效研究

• 批准号: 101618
• 金额: $ 160.11万
• 依托单位: RENEURON LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101618
• 关键词: Phase; II; Simon; Two; Stage

Disability affects approximately 50% of stroke survivors due to permanent loss of brain tissue. ReNeuron is testing the effectiveness of a unique stem cell product, called CTX, in disabled stroke patients. ReNeuron has developed CTX from human brain stem cells, with cell banks established to provide the large quantities needed for clinical use. The safety of CTX has been assessed in stroke-disabled patients in Scotland. Treatment of all patients in this Phase I clinical trial has been completed, with no reports to date of any serious side effects or worsening in disability in the patients. Sustained reductions in neurological impairment and spasticity have also been observed in most patients compared with their stable pre-treatment baseline performance. TSB support is needed to conduct a Phase II study in up to 41 patients with upper limb paralysis at 2-4 months after their strokes. This proposed clinical trial will determine if CTX produces clinically meaningful improvements in the use of the paralysed arm at 6 months post-treatment in a sufficient number of patients treated. Success in this project will represent a significant milestone for ReNeuron and for the wider stroke field.

由于脑组织永久性丧失，大约 50% 的中风幸存者会出现残疾。 ReNeuron 正在测试一种名为 CTX 的独特干细胞产品对残疾中风患者的有效性。 ReNeuron 从人脑干细胞中开发出 CTX，并建立了细胞库以提供临床使用所需的大量细胞。 CTX 的安全性已在苏格兰的中风致残患者中进行了评估。该一期临床试验中所有患者的治疗均已完成，迄今为止尚未有任何严重副作用或患者残疾恶化的报告。与稳定的治疗前基线表现相比，大多数患者的神经损伤和痉挛持续减少。需要 TSB 支持对多达 41 名中风后 2-4 个月出现上肢瘫痪的患者进行 II 期研究。这项拟议的临床试验将确定在治疗后 6 个月时，CTX 在足够数量的接受治疗的患者中是否能对瘫痪手臂的使用产生具有临床意义的改善。该项目的成功将代表 ReNeuron 和更广泛的中风领域的一个重要里程碑。